Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main ...

Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, directly to ...

Pfizer, Inc. (NYSE:PFE) is one of the high-margin pharma stocks to buy now. Bristol-Myers Squibb Company (NYSE:BMY) and ...

The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have ...

Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. The company has ...

Bristol Myers Squibb (BMY) stock slips as its anemia drug Reblozyl misses primary goal in a Phase 3 trial for myelofibrosis, ...

Bristol Myers Squibb & Co. (NYSE:BMY) on Friday announced topline results from the Phase 3 INDEPENDENCE trial evaluating ...

The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...

The reduced rate will still be almost 10 times the average monthly out-of-pocket costs paid by commercially insured patients.

Drugmakers will offer Eliquis at a 43% discount to uninsured U.S. patients, bypassing insurers and PBMs New $346 monthly ...

Bristol Myers and Pfizer will sell Eliquis directly to U.S. patients at a discounted rate with transparent pricing and ...